Advertisement

Topics

Amgen Pushes Ahead With ‘Son of Dmab’ For Treating Broken, Frail Bones

09:32 EST 9 Feb 2011 |

Folks who follow Amgen closely know there’s really been one main theme to this story the past couple years—Dmab, Dmab, Dmab. Also know as denosumab, this is the targeted antibody drug Amgen developed for bone disorders that is supposed to be biggest thing to emerge from its internal R&D pipeline in about 20 years (although [...]

Original Article: Amgen Pushes Ahead With ‘Son of Dmab’ For Treating Broken, Frail Bones

NEXT ARTICLE

More From BioPortfolio on "Amgen Pushes Ahead With ‘Son of Dmab’ For Treating Broken, Frail Bones"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Prostate Cancer
Prostate cancer (cancer de prostata) Prostate cancer (cancer de prostata) is a form of cancer that develops in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, there are cases of aggressive prostat...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...